Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Receives Neutral Rating from BTIG Research

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report)'s stock had its "neutral" rating reaffirmed by stock analysts at BTIG Research in a note issued to investors on Thursday,Benzinga reports.

Several other brokerages have also issued reports on VRNA. TD Cowen assumed coverage on shares of Verona Pharma PLC American Depositary Share in a research note on Monday, April 28th. They set a "buy" rating and a $100.00 price target for the company. Cantor Fitzgerald raised their price target on shares of Verona Pharma PLC American Depositary Share from $90.00 to $100.00 and gave the stock an "overweight" rating in a research note on Wednesday, June 11th. Canaccord Genuity Group restated a "hold" rating and set a $107.00 price target on shares of Verona Pharma PLC American Depositary Share in a research note on Wednesday. Piper Sandler set a $160.00 price objective on shares of Verona Pharma PLC American Depositary Share and gave the stock an "overweight" rating in a report on Monday, June 23rd. Finally, Wolfe Research started coverage on shares of Verona Pharma PLC American Depositary Share in a report on Tuesday, July 1st. They issued an "outperform" rating and a $170.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, Verona Pharma PLC American Depositary Share currently has a consensus rating of "Moderate Buy" and an average target price of $110.27.

Verona Pharma PLC American Depositary Share Trading Up 20.6%

VRNA opened at $104.77 on Thursday. The company has a debt-to-equity ratio of 1.07, a current ratio of 8.86 and a quick ratio of 8.73. Verona Pharma PLC American Depositary Share has a fifty-two week low of $16.91 and a fifty-two week high of $104.93. The firm has a market capitalization of $8.49 billion, a PE ratio of -52.39 and a beta of 0.24. The company's 50-day moving average is $82.60 and its 200 day moving average is $66.84.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The company reported $0.27 EPS for the quarter, beating the consensus estimate of ($0.22) by $0.49. The firm had revenue of $98.65 million during the quarter, compared to analysts' expectations of $41.47 million. As a group, research analysts predict that Verona Pharma PLC American Depositary Share will post -1.95 earnings per share for the current fiscal year.

Insider Buying and Selling at Verona Pharma PLC American Depositary Share

In related news, General Counsel Andrew Fisher sold 80,000 shares of the business's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $11.53, for a total transaction of $922,400.00. Following the sale, the general counsel owned 359,999 shares of the company's stock, valued at $4,150,788.47. The trade was a 18.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Mark W. Hahn sold 400,000 shares of the business's stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $11.40, for a total transaction of $4,560,000.00. Following the sale, the chief financial officer directly owned 12,278,992 shares in the company, valued at $139,980,508.80. The trade was a 3.15% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,965,800 shares of company stock worth $20,056,881. Insiders own 4.80% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. NBC Securities Inc. bought a new stake in Verona Pharma PLC American Depositary Share in the 1st quarter worth approximately $34,000. Geneos Wealth Management Inc. raised its stake in Verona Pharma PLC American Depositary Share by 44.2% during the 1st quarter. Geneos Wealth Management Inc. now owns 630 shares of the company's stock valued at $40,000 after buying an additional 193 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in Verona Pharma PLC American Depositary Share during the 1st quarter valued at $48,000. NewEdge Advisors LLC purchased a new stake in Verona Pharma PLC American Depositary Share during the 1st quarter valued at $58,000. Finally, Vermillion Wealth Management Inc. purchased a new stake in Verona Pharma PLC American Depositary Share during the 4th quarter valued at $46,000. Institutional investors own 85.88% of the company's stock.

About Verona Pharma PLC American Depositary Share

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.